Key result
Chemotherapeutic agents, particularly anthracyclines and trastuzumab, are leading causes of cardiotoxicity manifesting as heart failure and left ventricular systolic dysfunction.
This review summarizes current opinions and guidelines on the management of chemotherapy-induced cardiotoxicity, focusing on anthracyclines and trastuzumab.
Answers are grounded in this paper and cite their sources.
Supports vigilance for cardiotoxicity during anthracycline or trastuzumab therapy; leaves open optimal prevention and monitoring protocols.
Advances in chemotherapeutic agents over the past two decades have resulted in significantly improved cancer survival rates. Cardiac toxicity, however, has emerged as a leading cause of morbidity, both during and years after treatment. One of the most common manifestations of cardiotoxicity is that of heart failure and left ventricular systolic dysfunction. Consequently, the field of cardio-oncology is a rapidly emerging field of sub-specialty, with growing research interests in all aspects of management. In this review, current opinions and guidelines in this field are discussed, with particular focus on the most common culprits, the anthracyclines and the monoclonal antibody, trastuzumab.
No takes yet. Share an insight, caveat, or question.
Piper et al. (2015) conducted a review in Cardiotoxicity and Heart Failure. Chemotherapeutic agents (anthracyclines and trastuzumab) was evaluated. Chemotherapeutic agents, particularly anthracyclines and trastuzumab, are leading causes of cardiotoxicity manifesting as heart failure and left ventricular systolic dysfunction.
Synapse has enriched 10 related papers. Consider them for comparative context: